New research shows that the the longest-acting injectable PrEP, shows no adverse interactions with hormone therapy for trans ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

Match Health Collective today announced the launch of Pulse Health Sciences ("Pulse"), a new medical education and insights division co-founded by Jackson Choy, who will serve as President. Pulse ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

The submission is based on outcomes from the Phase III DELTA Teen trial of Anzupgo (delgocitinib) 20mg/g cream.

In today's economic landscape, where inflation and rising interest rates are a constant concern, companies are compelled to prioritize efficiency and cash flow management. This focus is essential not ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...